Home » Newsletters » BioWorld Science

BioWorld Science

July 27, 1999

View Archived Issues

Abbott makes major strides in R&D during Q2

Competitive Technologies' ribozymes offer promise in gene therapy approaches

Cerus initiates phase III U.S. trial of platelet pathogen inactivation system

Alza expands promotion of Ditropan XL for overactive bladder

Idec Pharmaceuticals development highlights during second quarter

AHP's pneumococcal conjugate vaccine receives priority review status

Clinical program initiated for CEP-1347 in neurodegenerative disease therapy

Fujisawa initiates enrollment in phase III RA trial of Prograf

Phase I trial results reported for MSI pulmonary delivery of morphine

Patient enrollment completed in Anogesic phase III trial

Progenics awarded two grants from NIH for HIV programs

Novel class of acetylcholine receptor ligands discovered by Sibia researchers

Cytokine production inhibitors from SB particularly useful for inflammation, osteoporosis

Chroman-based beta3-adrenoceptor agonists in development at Bayer

Novel BZ-site GABA-A receptor ligands disclosed by Sanofi-Synthelabo

New agents for glaucoma disclosed by Alcon in recent patent literature

Bayer presents new anticancer compounds that inhibit Raf kinase

Antiobesity compounds in the Novartis pipeline

Gacyclidine displays therapeutic window of up to one hour in rat model of focal cerebral ischemia

Dual antioxidant/nNOS inhibitor effective in animal models of cerebral ischemia and brain injury

Nitrosylated alpha-adrenoceptor antagonists as potential agents for impotence

FDA requests additional data to support n-docosanol NDA

BM-113: pharmacokinetics and metabolism in rats following oral and intravenous dosing

Magainin's Locilex cream not approvable says FDA

Elan to develop Antegren for chronic treatment of MS

Continuous infusion of toborinone preferable in heart failure developing after cardiac surgery

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...